InMed Pharmaceuticals

INM

Capitalización de mercado USD 7.25 M

Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the shareholders' equity of $1,075,007 as reported in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2026, was below the minimum shareholders' equity of $2,500,000 required for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1). The decline in the Company's shareholders' equity is attributable largely to transaction-related expenses accrued in connection with the Company's previously announced Agreement and Plan of Merger and Reorganization dated May 19, 2026 (as amended, the "Merger Agreement") entered into with Mentari Therapeutics, Inc. ("Mentari"), pursuant to which, among other things, the Company will merge with Mentari (the "Merger").

Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 30, 2026. The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at www.inmedpharma.com, www.sedarplus.ca and www.sec.gov.

Mentari Therapeutics, a privately held biotechnology enterprise dedicated to preventing migraines, has successfully secured an additional $200 million through a new private placement.

WALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 million private placement to leading healthcare investors.

Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.

Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered into an amendment (the "Amendment") to the previously announced definitive merger agreement (the "Agreement") for an all-stock transaction with Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp., a wholly-owned subsidiary of InMed, and Indigo Merger Sub II, LLC, a wholly-owned subsidiary of InMed. InMed also announced that it has filed a registration statement on Form S-4 (the "S-4") with the U.S. Securities and Exchange Commission (the "SEC") containing a preliminary proxy statement/prospectus and management information circular in connection with the proposed merger (as amended, the "Merger") and related transactions contemplated by the Agreement (the Merger together with such related transactions, the "Contemplated Transactions").

Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 3, 2026 informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq. As previously disclosed, the Company was notified by Nasdaq on March 27, 2026 that its common shares had failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days.

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

InMed Pharmaceuticals Inc. (INM) M&A Call Prepared Remarks Transcript

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating InMed Pharmaceuticals, Inc. (NASDAQ:  INM ) related to its merger with Mentari Therapeutics, Inc. Upon closing of the proposed transaction, InMed shareholders are expected to own approximately 1.51% of the combined company. Is it a fair deal?